We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+54.14%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.52B
AUM Growth
+$24M
(+1.6%)
Cap. Flow
-$83.5M
Cap. Flow
% of AUM
-5.5%
Top 10 Holdings %
Top 10 Hldgs %
56.06%
Holding
84
New
11
Increased
10
Reduced
18
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enliven Therapeutics
ELVN
|
+$39.4M |
| 2 |
BridgeBio Pharma
BBIO
|
+$37.2M |
| 3 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$31M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$28.6M |
| 5 |
Pliant Therapeutics
PLRX
|
+$18.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$50.1M |
| 2 |
Revolution Medicines
RVMD
|
+$45.1M |
| 3 |
Altimmune
ALT
|
+$42.8M |
| 4 |
VTYX
Ventyx Biosciences
VTYX
|
+$35.4M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$20.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.97% |
| 2 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
76
Amylyx Pharmaceuticals
AMLX
$2.54B
| – | – |
-550,000
| Closed | -$20.3M |
|
77
Arcutis Biotherapeutics
ARQT
$3.18B
| – | – |
-650,000
| Closed | -$9.62M |
|
78
Ascendis Pharma A/S
ASND
$16.8B
| – | – |
-50,000
| Closed | -$6.11M |
|
79
Immunovant
IMVT
$8.25B
| – | – |
-400,000
| Closed | -$7.1M |
|
80
Keros Therapeutics
KROS
$221M
| – | – |
-100,000
| Closed | -$4.8M |
|
|
81
Revolution Medicines
RVMD
$44B
| – | – |
-1,895,066
| Closed | -$45.1M |
|
|
VTYX
82
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-1,080,643
| Closed | -$35.4M |
|
|
YMAB
83
DELISTED
Y-mAbs Therapeutics
YMAB
| – | – |
-150,000
| Closed | -$732K |
|
|
MRTX
84
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-400,000
| Closed | -$18.1M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, Cormorant Asset Management held 84 positions worth $1.52B, up 1.6% from $1.49B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Cormorant Asset Management withdrew a net $83.5M in Q1 2023, closing 12 positions and reducing 18 holdings. Its most notable exit was Revolution Medicines, an estimated $45.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.
Against the trend, Cormorant Asset Management opened a new position in Enliven Therapeutics worth $42.4M.
- Cormorant Asset Management's largest Q1 2023 buy was Enliven Therapeutics: 1,936,133 shares worth $42.4M.
- Cormorant Asset Management added most to BridgeBio Pharma in Q1 2023, an estimated $37.2M increase.
- Cormorant Asset Management's biggest Q1 2023 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $50.1M.
- Cormorant Asset Management fully exited Revolution Medicines in Q1 2023, selling an estimated $45.1M.
- Cormorant Asset Management's ten largest holdings make up 56% of its $1.52B portfolio in Q1 2023.
- Cormorant Asset Management opened 11 new positions and closed 12 in Q1 2023.
- Cormorant Asset Management's portfolio value rose 1.6% quarter-over-quarter to $1.52B.
Based on Cormorant Asset Management's 13F filing for Q1 2023, filed 15 May 2023.